Terms: = Breast cancer AND PDGFRB, JTK12, 5159, P09619, ENSG00000113721, PDGF-R-beta, PDGFR1, CD140B, PDGFR, CD140b
189 results:
1. The relationship between cancer associated fibroblasts biomarkers and prognosis of breast cancer: a systematic review and meta-analysis.
Cui M; Dong H; Duan W; Wang X; Liu Y; Shi L; Zhang B
PeerJ; 2024; 12():e16958. PubMed ID: 38410801
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic Markers in Tyrosine Kinases Specific to Basal-like 2 Subtype of Triple-Negative breast cancer.
Limsakul P; Choochuen P; Jungrungrueang T; Charupanit K
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338684
[TBL] [Abstract] [Full Text] [Related]
3. Mechanism of Erianin anti-triple negative breast cancer based on transcriptomics methods and network pharmacology.
Li M; Zhao Y; Li H; Kang S; Deng X; Sheng M
Aging (Albany NY); 2024 Feb; 16(3):2848-2865. PubMed ID: 38329441
[TBL] [Abstract] [Full Text] [Related]
4. Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative breast cancer.
Gardi N; Chaubal R; Parab P; Pachakar S; Kulkarni S; Shet T; Joshi S; Kembhavi Y; Chandrani P; Quist J; Kowtal P; Grigoriadis A; Sarin R; Govindarajan R; Gupta S
Cancer Res Commun; 2024 Feb; 4(2):404-417. PubMed ID: 38315150
[TBL] [Abstract] [Full Text] [Related]
5. From nature to cancer therapy: Evaluating the Streptomyces clavuligerus secondary metabolites for potential protein kinase inhibitors.
Saini R; Kumari S; Singh A; Mishra A
J Cell Biochem; 2024 Jan; 125(1):59-78. PubMed ID: 38047468
[TBL] [Abstract] [Full Text] [Related]
6. Use of secondary prevention medications in metropolitan and non-metropolitan areas: an analysis of 41 925 myocardial infarctions in Australia.
Livori AC; Ademi Z; Ilomäki J; Pol D; Morton JI; Bell JS
Eur J Prev Cardiol; 2024 Mar; 31(5):580-588. PubMed ID: 37987181
[TBL] [Abstract] [Full Text] [Related]
7. Analysis of CD74 Occurrence in Oncogenic Fusion Proteins.
Vargas J; Pantouris G
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958963
[TBL] [Abstract] [Full Text] [Related]
8. Secretory breast cancer in a boy: A case report with genetic analysis using next-generation sequencing and literature review.
Deng L; Li Y; Zhong J
Medicine (Baltimore); 2023 Jul; 102(27):e34192. PubMed ID: 37417596
[TBL] [Abstract] [Full Text] [Related]
9. Heterogeneity of the Tumor Microenvironment Across Molecular Subtypes of breast cancer.
Kashyap D; Bal A; Irinike S; Khare S; Bhattacharya S; Das A; Singh G
Appl Immunohistochem Mol Morphol; 2023 Sep; 31(8):533-543. PubMed ID: 37358863
[TBL] [Abstract] [Full Text] [Related]
10. Analysis of stromal pdgfr-β and α-SMA expression and their clinical relevance in brain metastases of breast cancer patients.
Akanda MR; Ahn EJ; Kim YJ; Salam SMA; Noh MG; Lee TK; Kim SS; Lee KH; Moon KS
BMC Cancer; 2023 May; 23(1):468. PubMed ID: 37217880
[TBL] [Abstract] [Full Text] [Related]
11. An integrative approach for exploring the nature of fibroepithelial neoplasms.
Yun J; Heo W; Lee ES; Na D; Kang W; Kang J; Chae J; Lee D; Lee W; Hwang J; Yoo TK; Hong BS; Son HY; Noh DY; Lee C; Moon HG; Kim JI
Br J Cancer; 2023 Feb; 128(4):626-637. PubMed ID: 36522480
[TBL] [Abstract] [Full Text] [Related]
12. Combination therapy with chitosan/siRNA nanoplexes targeting PDGF-D and pdgfr-β reveals anticancer effect in breast cancer.
Şalva E; Özbaş S; Alan S; Özkan N; Ekentok-Atıcı C; Kabasakal L; Akbuğa J
J Gene Med; 2023 Feb; 25(2):e3465. PubMed ID: 36413571
[TBL] [Abstract] [Full Text] [Related]
13. The prognostic and predictive values of differential expression of exosomal receptor tyrosine kinases and associated with the PI3K/AKT/mTOR signaling in breast cancer patients undergoing neoadjuvant chemotherapy.
Guney Eskiler G; Kazan N; Haciefendi A; Deveci Ozkan A; Ozdemir K; Ozen M; Kocer HB; Yilmaz F; Kaleli S; Sahin E; Bilir C
Clin Transl Oncol; 2023 Feb; 25(2):460-472. PubMed ID: 36181664
[TBL] [Abstract] [Full Text] [Related]
14. Her2/EGFR-pdgfr pathway aberrations associated with tamoxifen response in metastatic breast cancer patients.
Malash I; Mansour O; Gaafar R; Shaarawy S; Abdellateif MS; Ahmed OS; Zekri AN; Bahnassy A
J Egypt Natl Canc Inst; 2022 Jul; 34(1):31. PubMed ID: 35871690
[TBL] [Abstract] [Full Text] [Related]
15. Isoforms of Neuropilin-2 Denote Unique Tumor-Associated Macrophages in breast cancer.
Dhupar R; Jones KE; Powers AA; Eisenberg SH; Ding K; Chen F; Nasarre C; Cen Z; Gong YN; LaRue AC; Yeh ES; Luketich JD; Lee AV; Oesterreich S; Lotze MT; Gemmill RM; Soloff AC
Front Immunol; 2022; 13():830169. PubMed ID: 35651620
[TBL] [Abstract] [Full Text] [Related]
16. Diverse roles of tumor-stromal PDGFB-to-pdgfrβ signaling in breast cancer growth and metastasis.
Shah S; Sizemore GM
Adv Cancer Res; 2022; 154():93-140. PubMed ID: 35459473
[TBL] [Abstract] [Full Text] [Related]
17. Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the Treatment of cancer: A Review.
Unnisa A; Chettupalli AK; Hussain T; Kamal MA
Anticancer Agents Med Chem; 2022; 22(20):3370-3381. PubMed ID: 35400324
[TBL] [Abstract] [Full Text] [Related]
18. PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1/p38
Lane R; Cilibrasi C; Chen J; Shah K; Messuti E; Mazarakis NK; Stebbing J; Critchley G; Song E; Simon T; Giamas G
Oncogene; 2022 May; 41(19):2749-2763. PubMed ID: 35393545
[TBL] [Abstract] [Full Text] [Related]
19. Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative breast cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Chen L; Jiang YZ; Wu SY; Wu J; Di GH; Liu GY; Yu KD; Fan L; Li JJ; Hou YF; Hu Z; Chen CM; Huang XY; Cao AY; Hu X; Zhao S; Ma XY; Xu Y; Sun XJ; Chai WJ; Guo X; Chen X; Xu Y; Zhu XY; Zou JJ; Yang WT; Wang ZH; Shao ZM
Clin Cancer Res; 2022 Jul; 28(13):2807-2817. PubMed ID: 35247906
[TBL] [Abstract] [Full Text] [Related]
20. Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation.
Tang YH; Rockstroh A; Sokolowski KA; Lynam LR; Lehman M; Thompson EW; Gregory PA; Nelson CC; Volpert M; Hollier BG
Breast Cancer Res; 2022 Jan; 24(1):8. PubMed ID: 35078508
[TBL] [Abstract] [Full Text] [Related]
[Next]
